Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Two-arm, Non Interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

NCT05044026 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05044026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05044026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Two-arm, Non Interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
September 20, 2012
Completion date
September 19, 2022
Enrollment
1,012 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis, primary myelofibrosis